中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2014年
8期
597-601
,共5页
张惠民%陈淑琴%牛刚%姜红叶%姚书忠
張惠民%陳淑琴%牛剛%薑紅葉%姚書忠
장혜민%진숙금%우강%강홍협%요서충
[主题词]宫颈肿瘤%宫颈上皮内瘤样病变%免疫组织化学%Zeste同源增强子2%p53%预后
[主題詞]宮頸腫瘤%宮頸上皮內瘤樣病變%免疫組織化學%Zeste同源增彊子2%p53%預後
[주제사]궁경종류%궁경상피내류양병변%면역조직화학%Zeste동원증강자2%p53%예후
Uterine cervical neoplasms%Cervical intraepithelial neoplasms%Immunohistochemistry%Enhancer of zeste homolog 2%p53%Prognosis
目的 探讨Zeste同源增强子2(EZH2)和p53蛋白在宫颈鳞状细胞癌(sCC)及癌前病变中的表达及临床意义.方法 采用链霉卵白素-过氧化物酶连结(SP)免疫组化方法,检测SCC(168例)、宫颈上皮内瘤样病变(CIN)Ⅱ(19例)、CINⅢ(35例)和正常宫颈(30例)组织中EZH2和p53蛋白的表达情况,分析EZH2和p53蛋白共同表达的关系以及EZH2和p53蛋白表达与SCC临床病理特征和预后的关系.结果 在正常宫颈、CIN、SCC组织中,EZH2蛋白的阳性表达率分别为6.7％(2/30)、37.0％ (20/54)和75.6％(127/168),p53蛋白的阳性表达率分别为3.3％(1/30)、20.4％(11/54)和39.3％ (66/168),差异均有统计学意义(均P＜0.05).168例SCC患者中,有淋巴结转移患者的EZH2和p53蛋白阳性表达率分别为82.9％和45.7％,无淋巴结转移患者的EZH2和p53蛋白阳性表达率分别为70.4％和34.7％,差异有统计学意义(P＜0.05).随访的143例SCC患者中,EZH2和p53阴性、EZH2或p53阳性、EZH2和p53阳性患者的肿瘤无进展生存时间(PFS)分别为(71.3±1.9)个月、(66.1±2.0)个月和(51.3±3.8)个月,三者间差异有统计学意义(P＜0.001).EZH2和p53阴性、EZH2或p53阳性、EZH2和p53阳性患者的总生存时间(OS)分别为(72.9±1.1)个月、(68.6±1.8)个月和(57.4±3.4)个月,三者间差异有统计学意义(P＜0.001).多因素分析显示,EZH2表达情况、淋巴结转移情况和肿瘤分期为影响SCC预后的独立因素.结论 EZH2和p53蛋白表达可能参与了SCC的发生和发展,其与SCC是否发生淋巴结转移及预后有关.
目的 探討Zeste同源增彊子2(EZH2)和p53蛋白在宮頸鱗狀細胞癌(sCC)及癌前病變中的錶達及臨床意義.方法 採用鏈黴卵白素-過氧化物酶連結(SP)免疫組化方法,檢測SCC(168例)、宮頸上皮內瘤樣病變(CIN)Ⅱ(19例)、CINⅢ(35例)和正常宮頸(30例)組織中EZH2和p53蛋白的錶達情況,分析EZH2和p53蛋白共同錶達的關繫以及EZH2和p53蛋白錶達與SCC臨床病理特徵和預後的關繫.結果 在正常宮頸、CIN、SCC組織中,EZH2蛋白的暘性錶達率分彆為6.7％(2/30)、37.0％ (20/54)和75.6％(127/168),p53蛋白的暘性錶達率分彆為3.3％(1/30)、20.4％(11/54)和39.3％ (66/168),差異均有統計學意義(均P＜0.05).168例SCC患者中,有淋巴結轉移患者的EZH2和p53蛋白暘性錶達率分彆為82.9％和45.7％,無淋巴結轉移患者的EZH2和p53蛋白暘性錶達率分彆為70.4％和34.7％,差異有統計學意義(P＜0.05).隨訪的143例SCC患者中,EZH2和p53陰性、EZH2或p53暘性、EZH2和p53暘性患者的腫瘤無進展生存時間(PFS)分彆為(71.3±1.9)箇月、(66.1±2.0)箇月和(51.3±3.8)箇月,三者間差異有統計學意義(P＜0.001).EZH2和p53陰性、EZH2或p53暘性、EZH2和p53暘性患者的總生存時間(OS)分彆為(72.9±1.1)箇月、(68.6±1.8)箇月和(57.4±3.4)箇月,三者間差異有統計學意義(P＜0.001).多因素分析顯示,EZH2錶達情況、淋巴結轉移情況和腫瘤分期為影響SCC預後的獨立因素.結論 EZH2和p53蛋白錶達可能參與瞭SCC的髮生和髮展,其與SCC是否髮生淋巴結轉移及預後有關.
목적 탐토Zeste동원증강자2(EZH2)화p53단백재궁경린상세포암(sCC)급암전병변중적표체급림상의의.방법 채용련매란백소-과양화물매련결(SP)면역조화방법,검측SCC(168례)、궁경상피내류양병변(CIN)Ⅱ(19례)、CINⅢ(35례)화정상궁경(30례)조직중EZH2화p53단백적표체정황,분석EZH2화p53단백공동표체적관계이급EZH2화p53단백표체여SCC림상병리특정화예후적관계.결과 재정상궁경、CIN、SCC조직중,EZH2단백적양성표체솔분별위6.7％(2/30)、37.0％ (20/54)화75.6％(127/168),p53단백적양성표체솔분별위3.3％(1/30)、20.4％(11/54)화39.3％ (66/168),차이균유통계학의의(균P＜0.05).168례SCC환자중,유림파결전이환자적EZH2화p53단백양성표체솔분별위82.9％화45.7％,무림파결전이환자적EZH2화p53단백양성표체솔분별위70.4％화34.7％,차이유통계학의의(P＜0.05).수방적143례SCC환자중,EZH2화p53음성、EZH2혹p53양성、EZH2화p53양성환자적종류무진전생존시간(PFS)분별위(71.3±1.9)개월、(66.1±2.0)개월화(51.3±3.8)개월,삼자간차이유통계학의의(P＜0.001).EZH2화p53음성、EZH2혹p53양성、EZH2화p53양성환자적총생존시간(OS)분별위(72.9±1.1)개월、(68.6±1.8)개월화(57.4±3.4)개월,삼자간차이유통계학의의(P＜0.001).다인소분석현시,EZH2표체정황、림파결전이정황화종류분기위영향SCC예후적독립인소.결론 EZH2화p53단백표체가능삼여료SCC적발생화발전,기여SCC시부발생림파결전이급예후유관.
Objective To investigate the expression and clinical significance of enhancer of zeste homolog 2 (EZH2) and p53 proteins in cervical squamous cell carcinoma (SCC) and cervical intraepithelial neoplasia (CIN).Methods The expression and distribution of EZH2 and p53 were determined with reference to clinicopathological features and patient survival.168 cervical SCC,19 CIN Ⅱ,35 CIN Ⅲ patients and 30 normal control cases were collected for immunohistochemical analysis.Results The expression of EZH2 in the normal cervix,CIN and SCC was 6.7％ (2/30),37.0％ (20/54) and 75.6％ (127/168),respectively,with a significant difference between them (P ＜ 0.05).The expression of p53 was 3.3％ (1/30),20.4％ (11/54) and 39.3％ (66/168),respectively,also (P ＜ 0.05).In the 168 SCC cases,the positive rate of EZH2 in the cases with lymph node metastasis was 82.9％,and that of p53 was 45.7％ ; the positive rate of EZH2/p53 protein expression in the cases with negative lymph nodes was 70.4％,and that of p53 was 34.7％,with a significant difference between the two subgroups (P ＜0.05).Among the 143 followed-up SCC patients,the EZH2 + p53 + cases had a progression-free survival of (51.3 ± 3.8) months,that of EZH2 + or p53 + cases was (66.1 ± 2.0) months,and that of EZH2-p53-cases was (71.3 ± 1.9) months,with a very significant difference among the three subgroups (P ＜ 0.001).The overall survival times of EZH2-p53-,EZH2 + or p53 +,and EZH2 + p53 + cases were (72.9 ± 1.1),(68.6 ± 1.8),and (57.4 ± 3.4) months,respectively,with a significant difference among the three subgroups (P ＜ 0.001).The multivariate analysis showed that EZH2 expression,lymph node metastasis and tumor staging were independent prognostic factors.Conclusions Both EZH2 and p53 proteins may play important roles in the occurrence and development of cervical squamous cell carcinoma.There is a close relationship between the expression of both EZH2 and p53 proteins and the prognosis of SCC patients.
